Corvus Pharmaceuticals (CRVS) Share-based Compensation (2015 - 2026)

Corvus Pharmaceuticals' Share-based Compensation history runs 12 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 111.83% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 88.65% increase from a year earlier, with the FY2025 full-year figure at $25.7 million, up 117.8% from the prior year.
• Share-based Compensation improved to $2.6 million in Q1 2026 per CRVS's latest filing, from $1.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $2.6 million in Q1 2026 and bottomed at $492000.0 in Q1 2023.
• The 5-year median for Share-based Compensation is $734000.0 (2024), against an average of $930823.5.
• Across the five-year window, Share-based Compensation plunged 42.46% in 2022 and soared 111.83% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $620000.0 in 2022, then declined by 7.74% to $572000.0 in 2023, then jumped by 42.13% to $813000.0 in 2024, then soared by 93.6% to $1.6 million in 2025, then surged by 68.36% to $2.6 million in 2026.
• Per Business Quant, the three latest CRVS Share-based Compensation figures stand at $2.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.2 million (Q3 2025).